^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ABCC1 overexpression

i
Other names: ATP Binding Cassette Subfamily C Member 1, ATP-binding cassette, sub-family C (CFTR/MRP), member 1, GS-X, MRP, MRP1, ABCC1
Entrez ID:
Related biomarkers:
7d
Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: A comprehensive review. (PubMed, Eur J Pharm Biopharm)
The projection of desirable binding and effect may be procured initially by molecular docking of the inhibitor with P-gp, enabling the reduction of preliminary trials in formulation development. Here, P-gp-mediated efflux and several possible outcomes to overcome the problems associated with currently prevalent cancer treatments are highlighted.
Review • Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
ABCC1 overexpression
10d
Overexpression of multidrug resistance-associated protein 1 protects against cardiotoxicity by augmenting the doxorubicin efflux from cardiomyocytes. (PubMed, J Gene Med)
Finally, we demonstrated that hiPSC-CM transduced with LV.MRP1 were protected against doxorubicin injury. In conclusion, we have shown that we can successfully overexpress MRP1 protein in hiPSC-CM, with functional transporter activity leading to protection against doxorubicin-induced toxicity.
Journal
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
ABCC1 expression • ABCC1 overexpression
|
doxorubicin hydrochloride
2ms
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor. (PubMed, Drug Resist Updat)
The therapeutic efficacy of talazoparib in cancer may be compromised by its susceptibility to MDR, which is attributed to its interactions with the ABCC1 or ABCG2 transporters. The overexpression of these transporters can potentially diminish the therapeutic impact of talazoparib in cancer treatment.
Journal • PARP Biomarker
|
ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
ABCG2 expression • ABCC1 overexpression
|
Talzenna (talazoparib)
2ms
Pan-cancer analysis of ABCC1 as a potential prognostic and immunological biomarker. (PubMed, Transl Oncol)
Furthermore, various in vitro and in vivo experiments substantiated the role of ABCC1 in promoting the progression of HCC, along with increased macrophage recruitment. Based on the results, we propose ABCC1 as a potentially valuable prognostic indicator and a prospective target for immune-based cancer therapies.
Journal • Pan tumor
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
ABCC1 expression • ABCC1 overexpression
6ms
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. (PubMed, Nat Commun)
The BCL-2 inhibitor Venetoclax is a promising agent for the treatment of acute myeloid leukemia (AML)...Consistent with ABCC1-specific export of glutathionylated substrates, inhibition of glutathione metabolism increases the potency of BCL-2 inhibitors. These results identify ABCC1 and glutathione metabolism as mechanisms limiting efficacy of BCL-2 inhibitors, which may pave the way to development of more effective therapies.
Journal • IO biomarker
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
ABCC1 overexpression
|
Venclexta (venetoclax)
10ms
Acquired AKT-inhibitor Resistance Is Mediated by ATP-binding Cassette Transporters in Endometrial Carcinoma. (PubMed, Anticancer Res)
In this study, we established a triciribine-resistant cell line from HEC-151 cells. Our data suggest that the mechanism of drug resistance in endometrial cancer cells is attributed to the increased expression of ABC transporters.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
ABCC1 overexpression
|
triciribine phosphate (PTX-200)
12ms
Inhibition of CD73 expression or A2AR blockade reduces MRP1 expression and increases the sensitivity of cervical cancer cells to cisplatin. (PubMed, Cell Biochem Funct)
The inhibition of CD73 expression with a CD73-targeted siRNA and A2AR blockade with the selective antagonist ZM241385 significantly decreased MRP1 expression and the extrusive capacity of CC cells, making them significantly more sensitive to CP treatment than cancer cells treated with MK-751, a specific MRP1 inhibitor. These results suggest CD73 inhibition or blocking ADO signaling through A2AR could be strategies to reverse CPR in patients with advanced or recurrent CC, which is characterized by very low response rates to CP (10%-20%).
Journal
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • MSH3 (MutS Homolog 3) • NT5E (5'-Nucleotidase Ecto)
|
ABCC1 overexpression • CD73 expression
|
cisplatin
1year
CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression. (PubMed, Anticancer Drugs)
CircSETDB1 knockdown also enhanced Ptx sensitivity in vivo. In conclusion, circSETDB1 regulated Ptx resistance of ovarian cancer by targeting miR-508-3p/ABCC1 axis.
Journal
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • MIR508 (MicroRNA 508) • SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1)
|
ABCC1 expression • ABCC1 overexpression
|
paclitaxel
2years
Growth hormone receptor antagonist sensitizes melanoma and hepatocarcinoma to drug treatments via downregulation of ABC transporters in vivo (AACR 2022)
We then tested the effect of the GHA on the efficacy of cisplatin in vivo...GHA mice were subcutaneously inoculated with mouse HCC (Hepa1 6 cells) and subsequently treated with sorafenib...Additionally, higher ABCC1 levels also lead to significantly decreased survival rate in HCC patients. Collectively, the results indicate that a GHA is effective in sensitizing both melanoma and HCC to available treatments in vivo and may be used as a therapeutic strategy for higher efficacy of tumor clearance.
Preclinical
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
ABCC1 overexpression
|
cisplatin • sorafenib